[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370554-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370554-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","genetic-insights-support-parp1-as-a-mediator-in-the-protective-association-of-atp-citrate-lyase-inhibitors-with-melanoma","Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma","","Drug-target Mendelian randomization (MR) is used to mimic ATP-citrate lyase (ACLY) inhibition and test causal links to 17 cancers, leveraging eQTLGen data for ACLY expression, deCODE plasma proteome data, and large-scale cancer GWAS consortia. Genetically proxied ACLY inhibition is strongly associated with lower melanoma risk. Proteome-wide MR screens 1517 plasma proteins, highlighting PARP1 via strong colocalization and mediation estimates, with robust validation supporting PARP1 as a mediator.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/genetic-insights-support-parp1-as-a-mediator-in-the-protective-association-of-atp-citrate-lyase-inhibitors-with-melanoma/370554/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/genetic-insights-support-parp1-as-a-mediator-in-the-protective-association-of-atp-citrate-lyase-inhibitors-with-melanoma/370554.png","ImageObject",300,407,{"name":42,"@type":43},"Aria Callaghan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What approach is used to evaluate whether ACLY inhibition causally affects cancer risk?","Question",{"text":63,"@type":64},"A drug-target Mendelian randomization (MR) framework is applied, using genetic instruments linked to ACLY expression to mimic long-term drug effects.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the protective association with melanoma established?",{"text":68,"@type":64},"Genetically proxied ACLY inhibition shows a strong association with reduced melanoma risk in a combined analysis of two independent outcome datasets.",{"name":70,"@type":61,"acceptedAnswer":71},"Which protein is identified as a potential mediator and what supports this finding?",{"text":72,"@type":64},"PARP1 is highlighted by proteome-wide MR screening and strong colocalization; mediation analysis further suggests PARP1 mediates about half of the protective effect, supported by follow-up and validation analyses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370554,1790672164,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","communications biology Article  \n\n| A Nature Portfolio journal |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s42003-025-07860-z](https://doi.org/10.1038/s42003-025-07860-z) |  |  |\n| Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma\u003Cbr> Check for updates |  |  |\n| Jiawen Lu1,2, Gloria Hoi-Yee Li 1, Jingyi Hu3 & Zhenqian Wang 1,2  |  |  |\n| ATP-citrate lyase(ACLY)inhibitors emerge asa promising anti-cancer strategy, yet their causal effects across various cancer types remain unclear. Here, we employ a drug-target Mendelian randomization (MR) approach using four cis-expression quantitative trait loci for blood ACLY gene expression as genetic instruments to mimic ACLY inhibition. We utilize genetic data from the eQTLGen consortium (N = 31,684) for ACLY expression, the deCODE study (N = 35,559) for plasma proteome, and largescale cancer genome-wide association studies consortia (N from 49,708to417,127)to investigate the association of genetically mimicked ACLY inhibitors with 17 cancers and identify potential mediating proteins. Genetically proxiedACLY inhibition is strongly associated with reduced melanoma risk(odds ratio [95% conﬁdence interval (CI)]: 0.85 [0.78, 0.92]) in a combined analysis of two independent outcome datasets. Proteome-wide MR screening 1517 plasma proteins identiﬁes 3 proteins associated with melanoma, with Poly [ADP-ribose] polymerase 1 (PARP1) showing strong colocalization support. Mediation analysis further suggests PARP1 as a mediator in the protective effect of ACLY inhibition on melanoma (mediated proportion [95% CI]: 51 .52%[5 .45%, 97 .58%]) . Follow-up and validation analyses support the robustness of these results. This study illuminates the therapeutic potential of ACLY inhibition in melanoma, with PARP1 implicated as a potential mediator, offering avenues for targeted interventions. |  |  |\n| ATP-citrate lyase(ACLY)is a pivotal cytosolic enzyme that links heightened glycolysis to increased lipogenesis by catalyzing the conversion of mitochondria-derived citrate into acetyl-coenzyme A (CoA)1,2. Initially, ACLY inhibitors were investigated for their ability to reduce the synthesis of low-density lipoprotein cholesterol (LDL-C), leading to their potential application in treating dyslipidemia and cardiovascular diseases3,4. However, as the role of metabolic reprogramming in cancer pathogenesis has become increasingly recognized, ACLY has emerged asa promising target for cancer therapy5. Aberrant ACLY upregulation has currently been observed in various cancers, including colorectal, lung, prostate, hepatocellular and pancreatic cancer, and melanoma6–13. Despite this prevalence, the therapeutic efﬁcacy of ACLY inhibitors remains insufﬁciently studied and contentious across distinct cancer types14. | Recent studies have unveiled the immunological functions of ACLY inhibitors beyond their role in de novo lipogenesis. For example, ACLY inhibitors demonstrated the capacity to inﬂuence macrophage M1/M2 polarization, impacting both local and systemic inﬂammatory proﬁles15. Elevated ACLY levels in sepsis patients show correlations with proinﬂammatory markers, like interleukin-6, soluble E-selectin, soluble vascular cell adhesion molecule-1, and lactic acid, indicating that inhibiting ACLY could potentially amplify the pro-inﬂammatory response of endothelial cells16. Moreover, ACLY regulation in upregulating programmed death ligand 1 (PD-L1) expression in cancer cells has been linked to immunosuppression, compromising antitumor efﬁcacy17. These studies explored the crucial mediating role of proteins in the intricate interplay of ACLY inhibitors on cancer pathophysiology. However, observational |  |\n\n1Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hong Kong, China. 2School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China. 3National Clini","cbCaify4Hn08wWwM","https://ap.wps.com/l/cbCaify4Hn08wWwM","pdf",2076400,"English","# Results\n## Study overview","[{\"question\":\"What approach is used to evaluate whether ACLY inhibition causally affects cancer risk?\",\"answer\":\"A drug-target Mendelian randomization (MR) framework is applied, using genetic instruments linked to ACLY expression to mimic long-term drug effects.\"},{\"question\":\"How is the protective association with melanoma established?\",\"answer\":\"Genetically proxied ACLY inhibition shows a strong association with reduced melanoma risk in a combined analysis of two independent outcome datasets.\"},{\"question\":\"Which protein is identified as a potential mediator and what supports this finding?\",\"answer\":\"PARP1 is highlighted by proteome-wide MR screening and strong colocalization; mediation analysis further suggests PARP1 mediates about half of the protective effect, supported by follow-up and validation analyses.\"}]","Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma | PDF",1790189110,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eda8c3b451c5e2cd24254b78b968eaf.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cf3b56feb5293fe982bda7305283af0.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba48d3d4a29637cd63d15ba02e7f378e.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cecf2dbca5a1c1bd1483c3583201ce55.webp",980,1301]